The Adulthood GH Deficiency Expert Working Group (EWG) was formed in 2023. In addition to testing and using the GloBE-Reg platform and stimulating the development of studies, the EWG will also develop a recommendation for a minimum dataset that should be collected in all adults with GH deficiency who may receive rhGH therapy. The EWG also has representation from industry and patient associations.
All EWGs have a Remit and a maximum duration of 2 years.
Current Activities
- Development of the minimum dataset for monitoring safety and effectiveness of rhGH in Adulthood GHD
Members:
| Adulthood GHD EWG | Tenure Start | Tenure End | |
| Gudmundur Johannsson | Chair, Gothenburg, Sweden | 2023 | 2025 |
| Andrew Hoffman | Chair, Stanford, USA | 2023 | 2025 |
| Deno Andrews | Chicago, USA | 2023 | 2025 |
| Beverly MK Biller | Boston, USA | 2023 | 2025 |
| Cesar Boguszewski | Curitiba, Brazil | 2023 | 2025 |
| Lisette Cespedes | Pfizer | 2023 | 2025 |
| Anne Bro Bjørnelund | Ascendis | 2023 | 2025 |
| Peter Clayton | Manchester, UK | 2023 | 2025 |
| Maria Fleseriu | Portland, USA | 2023 | 2025 |
| Judith Gebaeur | Lübeck, Germany | 2023 | 2025 |
| Ken Ho | Sydney, Australia | 2023 | 2025 |
| Michael Højby | Novo Nordisk | 2023 | 2025 |
| Jens Otto Jørgensen | Aarhus, Denmark | 2023 | 2025 |
| Xiaoping Luo | Wuhan, China | 2023 | 2025 |
| Brad Miller | Minneapolis, USA | 2023 | 2025 |
| Sebastian Neggers | Rotterdam, Netherlands | 2023 | 2025 |
| Lars Sävendahl | Stockholm, Sweden | 2023 | 2025 |
| Katherina Schilbach | Munich, Germany | 2023 | 2025 |
| Aimee Shu | Ascendis | 2023 | 2025 |
| Christian Strasburger | Berlin, Germany | 2023 | 2025 |
| Yutaka Takahashi | Kobe, Japan | 2023 | 2025 |
| Diana Vitali | SOD Italia | 2023 | 2025 |
| Kevin CJ Yuen | Phoenix, USA | 2023 | 2025 |
| Markus Zabransky | Sandoz | 2023 | 2025 |
| Ching Chen | RIGHT Study | NA | NA |
| Faisal Ahmed | GloBE-Reg Project Management | NA | NA |
Members of the Adulthood GH Deficiency can access a private area here
Last Modified